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Gavestinel Does Not Improve Outcome After Acute
Intracerebral Hemorrhage
An Analysis From the GAIN International and GAIN Americas Studies
E. Clarke Haley Jr, MD; John L.P. Thompson, PhD; Bruce Levin, PhD; Stephen Davis, MD;
Kennedy R. Lees, MD; John G. Pittman, MS; Janet T. DeRosa, MPH; Paul Ordronneau, PhD;
Devin L. Brown, MD; Ralph L. Sacco, MD; for the GAIN Americas and GAIN
International Investigators*
Background and Purpose—Glycine Antagonist in Neuroprotection (GAIN) International and GAIN Americas trials were
prospectively designed, randomized, placebo-controlled trials of gavestinel, a glycine-site antagonist and putative
neuroprotectant drug administered within 6 hours of suspected ischemic or hemorrhagic stroke. Both trials reported that
gavestinel was ineffective in ischemic stroke. This analysis reports the results in those with primary intracerebral
hemorrhage.
Methods—The primary hypothesis was that gavestinel treatment did not alter outcome, measured at 3 months by the
Barthel Index (BI), from acute intracerebral hemorrhage, based on pooled results from both trials. The BI scores were
divided into 3 groups: 95 to 100 (independent), 60 to 90 (assisted independence), and 0 to 55 (dependent) or dead.
Results—In total, 3450 patients were randomized in GAIN International (N1804) and GAIN Americas (N1646). Of
these, 571 were ultimately identified to have spontaneous intracerebral hematoma on baseline head computerized
tomography scan. The difference in distribution of trichotomized BI scores at 3 months between gavestinel and placebo
was not statistically significant (P0.09). Serious adverse events were reported at similar rates in the 2 treatment groups.
Conclusions—These observations from the combined GAIN International and GAIN Americas trials suggest that
gavestinel is not of substantial benefit or harm to patients with primary intracerebral hemorrhage. These findings are
similar to results previously reported in patients with ischemic stroke. (Stroke. 2005;36:1006-1010.)
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One of the major potential advantages of a successfulneuroprotectant drug for acute stroke would be its relative
safety compared with thrombolytic therapy. In fact, the ideal
neuroprotectant drug should be safe enough that it could be
administered to patients with suspected acute stroke, either
ischemic or hemorrhagic, before neuroimaging, thereby expedit-
ing treatment during the critical time window when the bio-
chemical events leading to infarction are in progress and poten-
tially modifiable. Moreover, some investigators have suggested
that treatment with neuroprotective drugs early in the course of
primary intracerebral hemorrhage might lessen the damage
related to the hemorrhage and improve outcome.1,2
Such a strategy was used in the design of 2 large multicenter
randomized, placebo-controlled clinical trials of gavestinel, a
specific antagonist at the glycine site of the N-methyl-D-
aspartate receptor, for acute stroke. The details of the design and
results of each of these trials, GAIN International3 and GAIN
Americas,4 have been published previously. In both trials,
patients with intracerebral hemorrhage were eligible for inclu-
sion, although the primary analysis was performed only on those
patients who did not have hemorrhagic stroke on a baseline head
computerized tomography scan obtained either before or within
12 hours of the initial dose of study medication. Preliminary
experience in human trials with gavestinel treatment of intracra-
nial hemorrhage was sparse.5,6 This report focuses on the safety
and potential efficacy of gavestinel in a much larger pooled
population of patients in GAIN International and GAIN Amer-
icas who had hemorrhagic stroke.
Patients and Methods
This study was prospectively designed to test the safety and
preliminary efficacy of gavestinel in acute primary intracerebral
hemorrhage. The primary null hypothesis to be tested was that
gavestinel treatment did not alter outcome from acute intracranial
hemorrhage when begun within 6 hours of the onset of symptoms.
This hypothesis was a secondary hypothesis of each of the main
trials. Another secondary hypothesis was that serious adverse events
were not more frequent with gavestinel treatment than with placebo.
It was recognized that neither Glycine Antagonist in Neuroprotection
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(GAIN) International nor GAIN Americas would enroll sufficient
numbers of patients with intracranial hemorrhage to make any
important inferences regarding either safety or efficacy of gavestinel,
so an analysis pooling the results from both trials was planned
prospectively. Because the target sample sizes were determined by
the number of nonhemorrhagic patients, there was no prespecified
effect size, power calculation, or sample size with respect to the
intracerebral hemorrhage patients. The protocols and consent forms
used for both trials were reviewed and approved by each participat-
ing institution’s institutional review board before beginning
enrollment.
The inclusion and exclusion criteria for both GAIN International
and GAIN Americas were nearly identical and have been published
previously.3,4 In summary, patients had to have had a suspected acute
ischemic or hemorrhagic stroke and have treatment begun within 6
hours of the onset of symptoms. Eligible patients should not have
had pre-existing disability and had to be awake or only slightly
drowsy with at least a mild motor deficit at the time treatment was
begun. Baseline head computerized tomography scans using a
standard protocol with at least 10-mm slice thickness were required
either before treatment or within 12 hours of the first dose. The scans
from both trials were sent for review by a central adjudication
committee comprising 3 independent neuroradiologists (see Appen-
dix 1) who classified each scan as either showing intracranial
hemorrhage or not. Those scans showing hemorrhage were subclas-
sified into categories as follows: primary intracerebral hematoma,
hemorrhagic infarction, subarachnoid hemorrhage, subdural hemor-
rhage, and intraventricular hemorrhage using standard published
criteria.7,8 Those patients judged to have primary intracerebral
hematoma are the subject of this report.
After informed consent was obtained, patients were randomly as-
signed (1:1) to receive either gavestinel or placebo, with stratification by
age (75 or younger or older than 75 years) and stroke severity (National
Institutes of Health Stroke Scale [NIHSS]9 scores categorized as 2 to 5,
6 to 13,14) yielding 6 strata. The study drug was given intravenously
over 3 days. Patients received either placebo or a total of 1800 mg of
gavestinel administered as a loading dose of 800 mg over 4 hours,
followed by 5 maintenance doses of 200 mg each over 15 minutes at 12,
24, 36, 48, and 60 hours after the start of the loading dose. Study
treatment was terminated if creatinine values exceeded 2.0 mg/dL
(178.8 mol/L) or if bilirubin, aspartate aminotransferase, or alanine
aminotransferase values exceeded 4-times the upper limit of reference
ranges.
The primary outcome was functional capability in activities of
daily living at 3 months as measured by the Barthel Index (BI).10 BI
scores were trichotomized as follows: 95 to 100 indicates indepen-
dence (little or no help required), 60 to 90 indicates assisted
independence (some help required), and 0 to 55 indicates depen-
dence (help required with most or all activities). Deaths were
included with the 0 to 55 group for the primary analysis but analyzed
separately for safety. The BI cut points were chosen based on
previous studies that established that scores of 60 and 95 defined
meaningful clinical subgroups.11,12 To minimize bias, the person
performing the BI at 3 months could not be a person involved in
caring for the patient during the initial hospitalization.
Secondary outcome measures included the BI at 7 days or hospital
discharge (whichever came sooner) and at 1 month; NIHSS score at 1
and 3 months; and the modified Rankin Scale13 at 1 and 3 months.
Additionally, a global outcome statistic similar to that used in the
National Institute of Neurological Disorders and Stroke rtPA Stroke
Trial12 was calculated.
Adverse events, both serious (eg, life-threatening, resulting in
death, or prolonging hospitalization) and nonserious, were recorded
in a contemporaneous fashion. Routine blood work obtained at
baseline and at the end of treatment was sent to a central laboratory
to screen for hematological, renal, and hepatic dysfunction. The
safety of participants in the trial was overseen by an independent
Safety and Efficacy Data Monitoring Committee (see Appendix 1).
Statistical Analysis
In each GAIN trial, the test of the primary null hypothesis used the
extended Mantel–Haenszel 2 test (1 degree of freedom), stratified by
baseline stroke severity and age group, to combine the evidence from
the 6 strata. This took account of the stratified randomization, which
minimizes any confounding arising from age and NIHSS differences
between strata. In the current analysis, the same approach was prespeci-
fied for the test of the primary null hypothesis. The data from the 12
strata (6 from each trial) were combined in a similarly stratified analysis
using the extended Mantel–Haenszel procedure; P0.05 (2-sided) was
considered statistically significant.
This procedure assumes that the odds ratios for treatment in the 2
trials are the same (the intracerebral hemorrhage rates in each may
differ). A likelihood ratio test was used to test this assumption. A
significant difference (ie, P0.05) would indicate a treatment by
trial interaction and that an analysis that combined the data from the
2 trials would be inappropriate. A stratified Cox proportional hazards
model compared survival over 3 months in the 2 trials. Both results
indicated that the data could be combined (P0.18, for the primary
analysis and P0.29, for survival).
Figure 1. Trial profile.
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All comparisons of baseline characteristics in gavestinel versus
placebo groups take stratification into account. A 2-way analysis of
variance for treatment group by stratum was used for continuous
variables, a stratified Wilcoxon rank-sum test for ordinal measures,
and a Mantel–Haenszel test across strata for categorical variables.
Results
From March 1998, through October 1999, 3450 patients were
randomized in GAIN International (N1804) and GAIN
Americas (N1646). Of these, 572 were judged by the Image
Adjudication Committee to have hemorrhagic stroke on the
baseline head computerized tomography scan (Figure 1). One
was not located intracerebrally, leaving 571 actual intracere-
bral hemorrhages. Two patients did not receive treatment and
were excluded from the analysis. Additionally, 5 patients (3
gavestinel and 2 placebo) were excluded because they had
received tissue plasminogen activator before randomization.
One patient randomized to gavestinel instead received pla-
cebo, whereas 2 patients randomized to placebo received
gavestinel. For the primary efficacy analysis, which used
intent-to-treat principles, there were 280 patients assigned
gavestinel versus 284 patients assigned placebo. The safety
analyses included all randomized and treated patients accord-
ing to the drug they actually received: 284 gavestinel patients
versus 285 placebo patients. Seven patients were missing
3-month BI scores. Earlier post-treatment assessments were
carried forward for 6 of these (4 gavestinel and 2 placebo).
One gavestinel patient was completely lost to follow-up and
was imputed to have the lowest possible BI score.
Table 1 outlines the baseline characteristics of the patients in
each treatment group. There was an approximate balance in the
age, race, sex, and time from onset of symptoms to initiation of
treatment. There were similar proportions of patients who had
small versus large hematomas and intraventricular extension of
the hemorrhage. Despite the stratified randomization, the gav-
estinel group had a median 2 point higher baseline NIHSS score
than placebo patients did. None of the differences in baseline
characteristics was statistically significant.
Mortality was not significantly different between the 2
groups (stratified Wald test z score0.878, P0.380;
relative hazard ratio0.843, 95% confidence interval0.575
to 1.235). In the efficacy population, 51 of 280 (18%)
gavestinel-treated patients died within 3 months compared
with 58 of 284 (20%) placebo patients. In the safety popula-
tion (n569), 54 of 284 (19%) gavestinel patients died
compared with 59 of 285 (21%) placebo patients.
Figure 2 shows the distribution of BI scores at 3 months
in the 2 treatment groups divided into the prespecified
cutoffs for independence, assisted independence, and de-
pendence or death. Overall, the difference in distribution
of 3-month BI scores favored gavestinel but did not reach
statistical significance (P0.091). Inclusion of the 5 pa-
tients receiving tissue plasminogen activator did not sig-
nificantly alter the results (P0.128). Analyses of the
secondary outcomes, including the modified Rankin Scale
and NIH Stroke Scale, failed to disclose any statistically
significant differences (Appendix 2).
The proportion of patients who reported serious adverse
events was similar in both groups (Table 2). There were no
important differences between the groups in the incidence of
nonserious adverse events, except that the proportion of patients
with elevated bilirubin (a known side effect of gavestinel) was
14% in the gavestinel group compared with 5% in the placebo
group. All bilirubin elevations were transient.
Figure 2. Distributions of BI scores and
mortality at 3 months. Differences in out-
come were not statistically significant
(extended Mantel–Haenszel 2 test).
TABLE 1. Baseline Characteristics of Patients With Intracerebral
Hematoma in GAIN Americas and GAIN International*
Gavestinel Placebo
No. 280 284
Age, meanSD 67.512.0 68.512.2
Proportion male, No. (%) 165 (58.9) 173 (60.9)
Proportion white, No. (%) 222 (79.3) 229 (80.6)
Baseline blood pressure:
Systolic, mm Hg (meanSD)
Diastolic, mm Hg (meanSD)
172.027.4
92.816.4
169.926.8
92.316.5
Baseline NIHSS score, median
(interquartile range)
15.0 (9.0–18.0) 13.0 (9.0–18.0)
Time from onset to treatment,
min (median, interquartile range)
278.0 (235.0–330.0) 290.0 (240.0–330.0)
Hemorrhage characteristics
Small, 2.5 cm, No. (%) 66 (23.6) 58 (20.6)
Large, 2.5 cm, No. (%) 214 (76.4) 224 (79.4)
Intraventricular extension, No. (%) 79 (28.2) 75 (26.4)
*None of the differences between gavestinel and placebo groups is statistically
significant at P0.05 2-sided. All comparisons take stratification into account. A
2-way analysis of variance for treatment group by stratum was used for age and
baseline blood pressure, a stratified Wilcoxon test for baseline NIHSS score and
time from onset to treatment, and a Mantel–Haenszel test across strata for
proportion male, proportion white, and hemorrhage characteristics.
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Discussion
This pooled analysis represents the largest clinical trial of a
putative neuroprotectant drug in patients with primary intrace-
rebral hemorrhage. This group of stroke patients has long been
neglected in stroke research. Previous studies have largely
focused on surgical interventions.14,15 Unfortunately, no statisti-
cally significant benefit of gavestinel treatment begun within 6
hours of intracerebral hemorrhage was seen in this trial. These
results are consistent with the reported observations in ischemic
stroke patients treated with gavestinel.3,4
The patients enrolled in this study were a highly selected
subgroup of patients with intracerebral hemorrhage. To be
eligible, patients had to be fully alert or only slightly drowsy,
and had to have at least a mild motor deficit. That 20% of
patients died within 3 months suggests that if patients with
intracerebral hemorrhage are selected with similar neurolog-
ical criteria at baseline, their outcomes may not be worse than
patients with similar deficits from ischemic stroke.3,4 Simi-
larly, the overall rate of serious adverse events (20%)
reported in this hemorrhagic stroke population was similar to
the rate reported in the ischemic stroke population.
Although this was a large clinical trial in intracerebral hem-
orrhage by historical standards, it is possible that a beneficial
treatment effect of gavestinel may have been missed because of
a type 2 error. The observed adjacent odds ratio and 95%
confidence interval was 1.22 (0.98 to 1.52) with the current
sample size. If the placebo outcomes remained the same and
assuming proportional adjacent odds, the proportion of favorable
outcomes in the gavestinel group would have had to be an
absolute 14% greater (ie, 42% versus 28% for BI 95) to have
been detectable with 90% power in a study of this size. For good
power to detect smaller differences, a much larger sample size
would have been required. However, the relatively small abso-
lute 5% difference in favor of gavestinel observed in the current
study, combined with the indifferent results obtained from the 2
larger studies in patients with acute ischemic stroke, offer little
encouragement for further clinical trials of this compound in
patients with intracerebral hemorrhage.
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